QIAGEN (NYSE:QGEN) Issues Quarterly Earnings Results, Beats Estimates By $0.03 EPS

QIAGEN (NYSE:QGEN) posted its quarterly earnings results on Sunday. The company reported $0.66 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.63 by $0.03, MarketWatch Earnings reports. QIAGEN had a net margin of 11.18% and a return on equity of 17.51%. During the same period last year, the firm earned $0.34 earnings per share.

QGEN stock traded up $0.32 during midday trading on Tuesday, reaching $47.94. The stock had a trading volume of 1,460,325 shares, compared to its average volume of 850,952. The firm has a market cap of $10.93 billion, a price-to-earnings ratio of 58.73, a PEG ratio of 1.29 and a beta of 0.41. QIAGEN has a twelve month low of $41.48 and a twelve month high of $59.00. The company has a quick ratio of 1.22, a current ratio of 1.46 and a debt-to-equity ratio of 0.52. The business has a fifty day simple moving average of $50.11 and a two-hundred day simple moving average of $50.93.

Several research firms recently issued reports on QGEN. Zacks Investment Research lowered shares of QIAGEN from a “buy” rating to a “hold” rating and set a $54.00 price target for the company. in a research report on Friday, April 9th. Berenberg Bank reissued a “buy” rating on shares of QIAGEN in a report on Friday, February 19th. DZ Bank reaffirmed a “neutral” rating on shares of QIAGEN in a report on Wednesday, April 7th. TheStreet raised QIAGEN from a “c+” rating to an “a-” rating in a research note on Wednesday, February 10th. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of QIAGEN in a report on Tuesday. Six investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $59.92.


QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers primary sample technology consumables, such as nucleic stabilization and purification kits designed for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.

Featured Article: VIX – Volatility Index

Earnings History for QIAGEN (NYSE:QGEN)

Receive News & Ratings for QIAGEN Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for QIAGEN and related companies with MarketBeat.com's FREE daily email newsletter.